333 related articles for article (PubMed ID: 29602064)
1. High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms.
Fernandez-Prada C; Sharma M; Plourde M; Bresson E; Roy G; Leprohon P; Ouellette M
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):165-173. PubMed ID: 29602064
[TBL] [Abstract][Full Text] [Related]
2. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
Mondelaers A; Sanchez-Cañete MP; Hendrickx S; Eberhardt E; Garcia-Hernandez R; Lachaud L; Cotton J; Sanders M; Cuypers B; Imamura H; Dujardin JC; Delputte P; Cos P; Caljon G; Gamarro F; Castanys S; Maes L
PLoS One; 2016; 11(4):e0154101. PubMed ID: 27123924
[TBL] [Abstract][Full Text] [Related]
3. A Telomeric Cluster of Antimony Resistance Genes on Chromosome 34 of Leishmania infantum.
Tejera Nevado P; Bifeld E; Höhn K; Clos J
Antimicrob Agents Chemother; 2016 Sep; 60(9):5262-75. PubMed ID: 27324767
[TBL] [Abstract][Full Text] [Related]
4. Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.
Gazanion É; Fernández-Prada C; Papadopoulou B; Leprohon P; Ouellette M
Proc Natl Acad Sci U S A; 2016 May; 113(21):E3012-21. PubMed ID: 27162331
[TBL] [Abstract][Full Text] [Related]
5. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.
Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531
[TBL] [Abstract][Full Text] [Related]
6. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility.
Santi AMM; Silva PA; Santos IFM; Murta SMF
Parasit Vectors; 2021 Jul; 14(1):366. PubMed ID: 34266485
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
Mondelaers A; Hendrickx S; Van Bockstal L; Maes L; Caljon G
J Antimicrob Chemother; 2018 Feb; 73(2):392-394. PubMed ID: 29165590
[TBL] [Abstract][Full Text] [Related]
9. MRPA-independent mechanisms of antimony resistance in Leishmania infantum.
Douanne N; Wagner V; Roy G; Leprohon P; Ouellette M; Fernandez-Prada C
Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():28-37. PubMed ID: 32413766
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.
de Moura TR; Santos ML; Braz JM; Santos LF; Aragão MT; de Oliveira FA; Santos PL; da Silva ÂM; de Jesus AR; de Almeida RP
Parasitol Res; 2016 Feb; 115(2):713-21. PubMed ID: 26481489
[TBL] [Abstract][Full Text] [Related]
11. Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.
Laffitte MC; Leprohon P; Légaré D; Ouellette M
Parasitol Res; 2016 Oct; 115(10):3699-703. PubMed ID: 27457482
[TBL] [Abstract][Full Text] [Related]
12. A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes.
Genest PA; Haimeur A; Légaré D; Sereno D; Roy G; Messier N; Papadopoulou B; Ouellette M
Mol Biochem Parasitol; 2008 Mar; 158(1):95-9. PubMed ID: 18164495
[TBL] [Abstract][Full Text] [Related]
13. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
[TBL] [Abstract][Full Text] [Related]
14. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
15. Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach.
Ibarra-Meneses AV; Corbeil A; Wagner V; Beaudry F; do Monte-Neto RL; Fernandez-Prada C
Front Cell Infect Microbiol; 2022; 12():954144. PubMed ID: 35992178
[TBL] [Abstract][Full Text] [Related]
16. Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines.
Andrade JM; Gonçalves LO; Liarte DB; Lima DA; Guimarães FG; de Melo Resende D; Santi AMM; de Oliveira LM; Velloso JPL; Delfino RG; Pescher P; Späth GF; Ruiz JC; Murta SMF
Parasit Vectors; 2020 Nov; 13(1):600. PubMed ID: 33256787
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum.
Sereno D; Holzmuller P; Lemesre JL
Acta Trop; 2000 Jan; 74(1):25-31. PubMed ID: 10643904
[TBL] [Abstract][Full Text] [Related]
18. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
20. Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.
Van den Kerkhof M; Van Bockstal L; Gielis JF; Delputte P; Cos P; Maes L; Caljon G; Hendrickx S
Parasitol Res; 2018 Nov; 117(11):3601-3612. PubMed ID: 30141075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
